Prevention of Acute Radiation Enteritis With Glutamine

NCT ID: NCT00828399

Last Updated: 2011-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ionizing radiation has cytotoxic effects, and is commonly used as treatment for neoplasm. A common adverse effect of radiation is acute diarrhoea. Glutamine is an aminoacid with antioxidant effects that can protect tissues of damage dued to radiation. The investigators designed a randomized, double-blind trial phase III to study if glutamine prevents acute radiation enteritis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Radiation Enteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glutamine

Group Type EXPERIMENTAL

Glutamine

Intervention Type DIETARY_SUPPLEMENT

Oral glutamine 30g/day

Whole protein

Group Type PLACEBO_COMPARATOR

Whole protein

Intervention Type DIETARY_SUPPLEMENT

Oral whole protein 30 g/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glutamine

Oral glutamine 30g/day

Intervention Type DIETARY_SUPPLEMENT

Whole protein

Oral whole protein 30 g/day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 yr
* Gynaecological,prostatic, rectal or other abdominal cancer
* Radiotherapy with/without chemotherapy

Exclusion Criteria

* life expectancy \< 1 yr
* Age \< 18 yr
* gut diseases: inflammatory bowel disease,sprue, irritable bowel disease...
* moderate to severe chronic renal failure
* hepatic cirrhosis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Castilla-León Health Service

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Complejo Asistencial de Leóm

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alfonso Vidal Casariego, MD

Role: PRINCIPAL_INVESTIGATOR

Sección de Endocrinología y Nutrición. Complejo Asistencial de León

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Complejo Asistencial de León.

León, Leon, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP, Frank AR, McKone TK, Urias RE, Pilepich MV, Novotny PJ, Martenson JA; North Central Cancer Treatment Group. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol. 2003 May 1;21(9):1669-74. doi: 10.1200/JCO.2003.05.060.

Reference Type RESULT
PMID: 12721240 (View on PubMed)

Giris M, Erbil Y, Oztezcan S, Olgac V, Barbaros U, Deveci U, Kirgiz B, Uysal M, Toker GA. The effect of heme oxygenase-1 induction by glutamine on radiation-induced intestinal damage: the effect of heme oxygenase-1 on radiation enteritis. Am J Surg. 2006 Apr;191(4):503-9. doi: 10.1016/j.amjsurg.2005.11.004.

Reference Type RESULT
PMID: 16531144 (View on PubMed)

Ersin S, Tuncyurek P, Esassolak M, Alkanat M, Buke C, Yilmaz M, Telefoncu A, Kose T. The prophylactic and therapeutic effects of glutamine- and arginine-enriched diets on radiation-induced enteritis in rats. J Surg Res. 2000 Apr;89(2):121-5. doi: 10.1006/jsre.1999.5808.

Reference Type RESULT
PMID: 10729239 (View on PubMed)

de Urbina JJ, Jorquera F, Culebras JM, Villares C, Gonzalez-Gallego J, Tunon MJ. Effects of parenteral nutrition supplemented with alanyl-glutamine on nutrition status in rats. JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4):262-5. doi: 10.1177/0148607105029004262.

Reference Type RESULT
PMID: 15961682 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001-2008-BecaSacyl

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glutathione and Fuel Oxidation in Aging
NCT01870193 COMPLETED EARLY_PHASE1
Energetics and Function in Older Humans
NCT02348762 COMPLETED PHASE1